Default company panoramic image
Nuvox logo3

NuvOx Pharma

NuvOx Pharma’s patented drug platform will treat cancer, stroke, heart attack and other diseases when oxygen deprivation is a contributing factor.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Tucson, AZ, USA
  • Currency USD
  • Founded March 2008
  • Employees 9
  • Website nuvoxpharma.com

Company Summary

NuvOx’s drug, NVX-108, increases tissue oxygenation. We are in Phase IB clinical trials to treat brain tumors in cooperation with radiation (RT). Brain tumors are hypoxic and NVX-108 improves response to RT. The market potential in cancer can be expanded to $1.4 billion by treating other tumor types. Other applications: stroke (83% decrease in brain damage), heart attack, hemorrhagic shock, traumatic brain injury and sickle cell crisis.

Team

  • Default avatar
    Jennifer Lynn Marshall
    Chief Financial Officer

    Ms. Marshall has been in accounting and finance for over 25 years and completed two Masters Degrees at the University of Arizona. Ms. Marshall has worked as a CFO in Manufacturing, Healthcare and Pharma Research industries. As CFO of NuvOx, Ms. Marshall is responsible for accounting, is involved in the financing activities of the company and assists in business development. She teaches accounting in the Eller College of Management at the U of A.

  • Evan 20  20square
    President and Chief Executive Officer

    Dr. Unger has founded three biotech companies. His first, ImaRx Pharmaceutical, developed 3 FDA approved drugs and was acquired by DuPont yielding a > 20x ROI. Dr. Unger’s second company, ImaRx Therapeutics, went public and performed clinical trials with a technology to treat stroke. Dr. Unger co-founded NuvOx. He is inventor on 113 issued US patents, a board-certified radiologist and professor of radiology and BME at the University of Arizona.

  • Default avatar
    David Wilson
    Chief Business Officer

    Dr. Wilson has over 20 years experience developing and commercializing Medical Products that continue to generate $2B/year. He effectively leads programs that build value for collaborators, shareholders and employees and has had leadership responsibility creating $4B worth of shareholder value in Biotechnology companies.

    www.linkedin.com/pub/david-wilson/0/7a8/465/

Advisors

  • Default avatar
    Lawrence Hecker
    Lawyer
    Unconfirmed
    Default avatar
    Julie Klewer
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Desert Angels
    Unconfirmed
    Default avatar
    David Wilson
    Chief Business Officer
    Unconfirmed